Albemarle Corporation $ALB Stake Boosted by University of Texas Texas AM Investment Management Co.

University of Texas Texas AM Investment Management Co. boosted its holdings in shares of Albemarle Corporation (NYSE:ALB) by 3,416.3% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 9,951 shares of the specialty chemicals company’s stock after buying an additional 9,668 shares during the quarter. University of Texas Texas AM Investment Management Co.’s holdings in Albemarle were worth $1,053,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently bought and sold shares of ALB. Sigma Planning Corp boosted its stake in shares of Albemarle by 2.3% during the 1st quarter. Sigma Planning Corp now owns 2,952 shares of the specialty chemicals company’s stock worth $530,000 after acquiring an additional 66 shares during the period. Commonwealth of Pennsylvania Public School Empls Retrmt SYS raised its stake in Albemarle by 0.3% in the 1st quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 27,452 shares of the specialty chemicals company’s stock valued at $4,928,000 after acquiring an additional 75 shares during the period. Allspring Global Investments Holdings LLC lifted its holdings in Albemarle by 0.6% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 11,664 shares of the specialty chemicals company’s stock valued at $2,082,000 after purchasing an additional 75 shares during the last quarter. Cadence Wealth Management LLC lifted its holdings in Albemarle by 1.8% during the 1st quarter. Cadence Wealth Management LLC now owns 4,982 shares of the specialty chemicals company’s stock valued at $894,000 after purchasing an additional 87 shares during the last quarter. Finally, Parkside Financial Bank & Trust boosted its position in Albemarle by 7.0% during the second quarter. Parkside Financial Bank & Trust now owns 1,584 shares of the specialty chemicals company’s stock worth $214,000 after purchasing an additional 103 shares during the period. Institutional investors own 92.87% of the company’s stock.

Albemarle Stock Performance

NYSE:ALB opened at $99.03 on Monday. The stock has a market cap of $11.69 billion, a P/E ratio of 23.92, a PEG ratio of 0.59 and a beta of 1.34. The stock has a 50 day simple moving average of $107.59 and a 200 day simple moving average of $147.87. The company has a current ratio of 2.34, a quick ratio of 1.57 and a debt-to-equity ratio of 0.21. Albemarle Corporation has a 1-year low of $89.77 and a 1-year high of $221.00.

Albemarle (NYSE:ALB) last released its quarterly earnings results on Wednesday, November 4th. The specialty chemicals company reported $2.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.53 by $0.05. Albemarle had a return on equity of 14.91% and a net margin of 10.40%. The business had revenue of $1.55 billion during the quarter, compared to the consensus estimate of $1.52 billion. During the same period in the previous year, the company posted ($0.19) EPS. The firm’s quarterly revenue was up 18.8% on a year-over-year basis. Research analysts anticipate that Albemarle Corporation will post 11.23 earnings per share for the current year.

Albemarle Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, January 4th. Stockholders of record on Friday, December 18th will be issued a dividend of $0.41 per share. The ex-dividend date of this dividend is Friday, December 18th. This represents a $1.64 dividend on an annualized basis and a dividend yield of 1.7%. Albemarle’s dividend payout ratio (DPR) is currently 39.61%.

Key Headlines Impacting Albemarle

Here are the key news stories impacting Albemarle this week:

• Positive Sentiment: Albemarle reported third-quarter adjusted earnings of $2.58 per share, ahead of estimates, on $1.55 billion in revenue—also above forecasts and up 18.8% year over year. Higher lithium pricing, strong demand, cost reductions and improved Specialties profits supported the results. Albemarle Q3 Earnings Call Highlights Cost Discipline and Lithium Demand
• Positive Sentiment: Scotiabank maintained its “Sector Outperform” rating and $190 price target, estimating EPS of $11.64 for FY2026 and $14.15 for FY2027—above the cited current-year consensus estimate. Albemarle analyst coverage
• Positive Sentiment: Truist reaffirmed its “buy” rating, though it lowered its price target to $170 from $185. Truist rating information
• Neutral Sentiment: RBC cut its target to $119 from $129 but retained an “outperform” rating, reflecting a more cautious valuation alongside continued optimism about the shares. RBC rating information
• Negative Sentiment: Barclays lowered its target to $95 from $109 and kept an “equal weight” rating, pointing to a less favorable near-term risk-reward view. Lithium prices remain volatile, a potential source of uncertainty for earnings. Barclays rating information

Analyst Ratings Changes

Several brokerages have recently weighed in on ALB. Truist Financial reissued a “buy” rating and issued a $170.00 price objective (down from $185.00) on shares of Albemarle in a research report on Friday. Weiss Ratings upgraded shares of Albemarle from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Wednesday. UBS Group reduced their target price on shares of Albemarle from $175.00 to $150.00 and set a “buy” rating for the company in a report on Monday, October 5th. JPMorgan Chase & Co. reduced their target price on shares of Albemarle from $160.00 to $140.00 and set a “neutral” rating for the company in a report on Tuesday, August 25th. Finally, Citigroup decreased their price target on shares of Albemarle from $175.00 to $125.00 and set a “buy” rating on the stock in a research note on Thursday, October 22nd. Fifteen analysts have rated the stock with a Buy rating, eight have given a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $177.64.

Albemarle Company Profile

Albemarle Corporation is a specialty chemicals company that produces lithium, bromine and refining catalysts. Its products serve industries including energy storage, transportation, electronics, petroleum refining and pharmaceuticals.

The company supplies lithium compounds used in rechargeable batteries and other applications. It also makes bromine-based products for uses such as flame retardants and water treatment, along with catalysts used in refining petroleum.

Albemarle traces its history to 1887 and is headquartered in Charlotte, North Carolina.